Results 81 to 90 of about 4,040 (201)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient [PDF]

open access: yes, 2022
Novel carbapenem-β-lactamase inhibitor combination, imipenem/relebactam (IMI-REL), has been recently approved for treatment of infections with limited or no alternative treatment options.
Federica Bovo   +7 more
core   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

open access: yesClinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen   +3 more
wiley   +1 more source

A review of antibiotic safety in pregnancy—2025 update

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen   +8 more
wiley   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

open access: yesJournal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm   +16 more
doaj   +1 more source

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

open access: yesClinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg   +11 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

open access: yesMicrobiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang   +13 more
doaj   +1 more source

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

open access: yesEFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards)   +28 more
wiley   +1 more source

Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016 [PDF]

open access: yes, 2019
The mechanism of resistance in carbapenem-resistant Enterobacteriaceae (CRE) has therapeutic implications. We comprehensively characterized emerging mechanisms of resistance in CRE between 2013 and 2016 at a health system in Northern California.
Andermann, Tessa   +15 more
core   +1 more source

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten. [PDF]

open access: yes
Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the ...
Abdelhamed, Ayman M   +16 more
core   +2 more sources

Infections Management in the Lung Transplant Setting in Italy: A Web‐Survey

open access: yesTransplant Infectious Disease, Volume 27, Issue 2, March/April 2025.
A web survey has revealed significant variation in infection management practices across Italian lung transplant centers. These differences encompass key aspects of infection prevention and control, including antibiotic protocols and cytomegalovirus prophylaxis, underscoring a lack of consistency in fundamental strategies.
Andrea Lombardi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy